IE791966L - Microparticle drug delivery - Google Patents

Microparticle drug delivery

Info

Publication number
IE791966L
IE791966L IE791966A IE196679A IE791966L IE 791966 L IE791966 L IE 791966L IE 791966 A IE791966 A IE 791966A IE 196679 A IE196679 A IE 196679A IE 791966 L IE791966 L IE 791966L
Authority
IE
Ireland
Prior art keywords
drug delivery
microparticles
microparticle drug
reproductive organs
female reproductive
Prior art date
Application number
IE791966A
Other versions
IE48851B1 (en
Original Assignee
Stolle Res And Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Res And Dev Corp filed Critical Stolle Res And Dev Corp
Publication of IE791966L publication Critical patent/IE791966L/en
Publication of IE48851B1 publication Critical patent/IE48851B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Microparticles for the treatment of the internal female reproductive organs, comprise microparticles of a pharmaceutical agent incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles being capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus. [GB2034182A]
IE1966/79A 1978-10-17 1979-10-16 Microparticle drug delivery system IE48851B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95210978A 1978-10-17 1978-10-17
US96738078A 1978-12-07 1978-12-07

Publications (2)

Publication Number Publication Date
IE791966L true IE791966L (en) 1980-04-17
IE48851B1 IE48851B1 (en) 1985-05-29

Family

ID=27130325

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1966/79A IE48851B1 (en) 1978-10-17 1979-10-16 Microparticle drug delivery system

Country Status (13)

Country Link
AU (1) AU528186B2 (en)
CA (1) CA1143289A (en)
CH (1) CH645545A5 (en)
DE (1) DE2940146A1 (en)
FR (1) FR2439014A1 (en)
GB (1) GB2034182B (en)
IE (1) IE48851B1 (en)
IL (1) IL58471A (en)
IT (1) IT1124572B (en)
NL (1) NL184723C (en)
NZ (1) NZ191837A (en)
PH (1) PH25638A (en)
SE (1) SE7908520L (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
US4816257A (en) * 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US5688519A (en) * 1987-04-06 1997-11-18 Leonard; Robert J. Flash-flow fused medicinal implants
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
DE3785033T2 (en) * 1987-07-21 1993-10-07 Stolle Res & Dev Method for obtaining immunoregulatory factors by mammalian immunization.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
FR2620335A1 (en) * 1987-09-15 1989-03-17 Berdal Pascal PHARMACEUTICAL PRESENTATION POTENTIALIZING THE CYTOTROPHIC EFFECT OF SERUMS AND / OR ANTIBODY ANTIBODIES ANIMALS AND / OR HUMANS
US5084277A (en) * 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
BR9815499A (en) 1997-07-02 2001-01-02 Euro Celtique Sa Prolonged anesthesia in joints and body spaces.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3594468A (en) * 1969-04-01 1971-07-20 Vincent R Saurino Germicidal compositions
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3875300A (en) * 1972-12-18 1975-04-01 Ortho Pharma Corp Composition for sustained release of a medicament and method of using same
AU513400B2 (en) * 1976-03-04 1980-11-27 Commonwealth Serum Laboratories Commission Biodegradable, sustained release composition

Also Published As

Publication number Publication date
CH645545A5 (en) 1984-10-15
NL184723C (en) 1989-10-16
SE7908520L (en) 1980-04-18
NL7907432A (en) 1980-04-21
IT7926288A0 (en) 1979-10-05
NZ191837A (en) 1984-07-31
DE2940146C2 (en) 1991-12-05
IL58471A0 (en) 1980-01-31
FR2439014B1 (en) 1983-12-09
CA1143289A (en) 1983-03-22
AU5169679A (en) 1980-04-24
FR2439014A1 (en) 1980-05-16
PH25638A (en) 1991-08-31
GB2034182A (en) 1980-06-04
AU528186B2 (en) 1983-04-21
DE2940146A1 (en) 1980-04-30
IE48851B1 (en) 1985-05-29
NL184723B (en) 1989-05-16
GB2034182B (en) 1983-07-27
IL58471A (en) 1983-05-15
IT1124572B (en) 1986-05-07

Similar Documents

Publication Publication Date Title
US6444224B1 (en) Intra-vaginal device for pigs
SE7908520L (en) SYSTEM FOR ADMINISTRATION OF MEDICINAL PRODUCTS IN THE FORM OF MICROPARTICLES
AU564372B2 (en) Introducing nutrients into ruminant animals
EP0862396A4 (en) VAGINAL RING WITH INSERABLE CORE CONTAINING MEDICAMENT
EG20401A (en) Process for preparing of veterinary composition for the treatment of gastric acid related deseases in animals
TW429154B (en) A controlled release formulation for poorly soluble basic drugs
Hamra et al. Comparison of progesterone sponges, cronolone sponges and controlled internal drug release dispensers on fertility in anestrous ewes
DE69231291D1 (en) Vaccination system with a single dose
EP0016051A1 (en) Contraceptive-antivenereal disease tampon
Ainsworth et al. A controlled internal drug-release dispenser containing progesterone for control of the estrous cycle of ewes
Rathbone et al. Conceptual and commercially available intravaginal veterinary drug delivery systems
EP0873751A3 (en) Pharmaceutical product for application to uterus mucosa
Lev-Ran Secondary amenorrhea resulting from uncontrolled weight-reducing diets
Pharriss et al. Steroid delivery systems for contraception
Beck et al. Long-acting steroidal contraceptive systems
US3428729A (en) Controlled release formulation
Gross A technique for sustained synchronization of hamster estrous cycles by hormonal means
Machado et al. Efficacy of norethindrone acetate and norgestomet implants in suppressing estrus in female beef cattle
Vickery et al. Antifertiflty Effects in the Rabbit by Continuous Low Release of Progestin from an Intrauterine Device
Asch et al. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486
Kesler Remotely delivered contraception with needle-less norgestomet implants
Jakobsen The influence of oestrogenic hormones on the prostate; oestrogenic reactions in the human prostate after artificial hormone administration, in the normal human prostate at birth and in cases of senile hyperplasia of the prostate
WRENN et al. A new technique for introducing IUDs into rat uteri
Kabiraj et al. Effects of hysterectomy, administration of uterine extract, posterior pituitary extract and aspirin on the length of pseudopregnancy in rats
Klochkov et al. Effect of continuous illumination on the reproductive function in rats. Aftereffects

Legal Events

Date Code Title Description
MM4A Patent lapsed